Cathepsin B and Plasma Kallikrein Are Reliable Biomarkers to Discriminate Clinically Significant Hepatic Fibrosis in Patients with Chronic Hepatitis-C Infection

Cathepsin B and Plasma Kallikrein Are Reliable Biomarkers to Discriminate Clinically Significant Hepatic Fibrosis in Patients with Chronic Hepatitis-C Infection

We aimed to determine the biomarker performance of the proteolytic enzymes cathepsin B (Cat B) and plasma kallikrein (PKa) and transforming growth factor (TGF)-β to detect hepatic fibrosis (HF) in chronic hepatitis C (CHC) patients. We studied 53 CHC patients and 71 healthy controls (HCs). Hepatic-d...

Full description

Saved in:
Bibliographic Details
Published in:Microorganisms (Basel) Vol. 10; no. 9; p. 1769
Main Authors: Zanelatto, Alexia de Cassia Oliveira, Lacerda, Gilmar de Souza, Accardo, Camila de Melo, Rosário, Natalia Fonseca do, Silva, Andréa Alice da, Motta, Guacyara, Tersariol, Ivarne Luis Dos Santos, Xavier, Analucia Rampazzo
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 01-09-2022
MDPI
Subjects:
Biological markers
Biomarkers
Biopsy
Blood & organ donations
Blood platelets
Cathepsin B
Cathepsins
chronic hepatitis C
Chronic infection
Clinical significance
Diagnosis
Enzymes
Fibrosis
Genotype & phenotype
Growth factors
HCV
Health aspects
hepatic fibrosis
Hepatitis
Hepatitis C
Infections
Inflammation
Kallikrein
Laboratories
Liver cancer
Liver diseases
Metabolism
Plasma
Plasma kallikrein
Protein kinase A
Proteolysis
Proteolytic enzymes
Serum levels
TGF-β
Transforming growth factor-b
Viral infections
Brazil
United States > US
TGF-β
HCV
plasma kallikrein
hepatic fibrosis
cathepsin B
chronic hepatitis C
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to determine the biomarker performance of the proteolytic enzymes cathepsin B (Cat B) and plasma kallikrein (PKa) and transforming growth factor (TGF)-β to detect hepatic fibrosis (HF) in chronic hepatitis C (CHC) patients. We studied 53 CHC patients and 71 healthy controls (HCs). Hepatic-disease stage was determined by liver biopsies, aminotransferase:platelet ratio index (APRI) and Fibrosis (FIB)4. Hepatic inflammation and HF in CHC patients were stratified using the METAVIR scoring system. Cat-B and PKa activities were monitored fluorometrically. Serum levels of TGF-β (total and its active form) were determined using ELISA-like fluorometric methods. Increased serum levels of Cat B and PKa were found (p < 0.0001) in CHC patients with clinically significant HF and hepatic inflammation compared with HCs. Levels of total TGF-β (p < 0.0001) and active TGF-β (p < 0.001) were increased in CHC patients compared with HCs. Cat-B levels correlated strongly with PKa levels (r = 0.903, p < 0.0001) in CHC patients but did not correlate in HCs. Levels of Cat B, PKa and active TGF-β increased with the METAVIR stage of HF. Based on analyses of receiver operating characteristic (ROC) curves, Cat B and PKa showed high diagnostic accuracy (area under ROC = 0.99 ± 0.02 and 0.991 ± 0.007, respectively) for distinguishing HF in CHC patients from HCs. Taken together, Cat B and PKa could be used as circulating biomarkers to detect HF in HCV-infected patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2076-2607
2076-2607
DOI:10.3390/microorganisms10091769